SCHEMBL8513

SCHEMBL8513

O=C1CCc2ccc(OCCCCBr)cc2N1

nearest known ligand 0.71

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
MAOB P27338 19/20 0.71
MAOA P21397 18/20 0.71

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29460203 1.00 MAOB (0.71) MAOBMAOA
SCHEMBL11070224 0.99 MAOB (0.72) MAOBMAOA
SCHEMBL30546591 0.96 MAOB (0.70) MAOBMAOA
SCHEMBL252282 0.96 MAOB (0.70) MAOBMAOA
SCHEMBL2842062 0.93 MAOB (0.80) MAOBMAOA
SCHEMBL17848639 0.92 MAOB (0.68) MAOBMAOA
SCHEMBL29923843 0.92 MAOB (0.68) MAOBMAOA
SCHEMBL1036438 0.89 MAOB (0.67) MAOBMAOA
SCHEMBL14188953 0.88 MAOB (0.57) MAOBMAOA
SCHEMBL11276922 0.88 MAOB (0.65) MAOBMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 361 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115340494-A Synthesis method of high-purity aripiprazole 安徽修一制药有限公司 2022-11-15 CN claimed
CN-113214150-A Synthesis of high-purity aripiprazole and preparation method of hydrate particles thereof 北京逸诚医药科技有限公司 2021-08-06 CN claimed
EP-2408748-A2 ARIPIPRAZOLE SALTS Kozluk, Tomasz (PL) 2012-01-25 EP claimed
WO-2011030213-A8 IMPROVED PROCESS FOR THE PREPARATION OF 7-(4-BROMOBUTOXY) 3,4-DIHYDROCARBOSTYRIL, A PRECURSOR OF ARIPIPRAZOLE JUBILANT LIFE SCIENCES LIMITED (IN) 2011-05-19 WO claimed
WO-2011030213-A1 IMPROVED PROCESS FOR THE PREPARATION OF 7.(4-BROMOBUTOXY) 3,4-DIHYDROCARBOSTYRIL, A PRECURSOR OF ARIPIPRAZOLE JUBILANT ORGANOSYS LIMITED (IN) 2011-03-17 WO claimed
WO-2010107329-A2 ARIPIPRAZOLE SALTS KOZLUK TOMASZ (PL) 2010-09-23 WO claimed
US-20100130744-A1 PROCESS FOR THE PREPARATION OF ARIPIPRAZOLE AUROBINDO PHARMA LTD (IN) 2010-05-27 US claimed
US-20090198059-A1 Process for the preparation of polymorphs, solvates of aripiprazole using aripirazole acid salts SATYANARAYANA CHAVA 2009-08-06 US claimed
WO-2008146156-A2 AN IMPROVED PROCESS FOR THE PREPARATION OF ARIPIPRAZOLE AUROBINDO PHARMA LIMITED (IN) 2008-12-04 WO claimed
US-7361756-B2 Method of making 7-(4-bromobutoxy)-3,4-dihydrocarbostyril TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2008-04-22 US claimed
JP-2007517916-A 2007-07-05 JP claimed
EP-1797039-A1 PROCESS FOR THE PREPARATION OF POLYMORPHS, SOLVATES OF ARIPIPRAZOLE USING ARIPIPRAZOLE ACID SALTS Matrix Laboratories Ltd (IN) 2007-06-20 EP claimed
EP-1765782-A1 METHOD OF MAKING 7-(4-BROMOBUTOXY)-3,4-DIHYDROCARBOSTYRIL Teva Pharmaceutical Industries Ltd (IL) 2007-03-28 EP claimed
US-20060258869-A1 Process for the preparation of aripiprazole ALEMBIC LIMITED (IN) 2006-11-16 US claimed
EP-1711466-A1 PROCESS FOR PREPARING ARIPIPRAZOLE Teva Pharmaceutical Industries Ltd (IL) 2006-10-18 EP claimed
WO-2006030446-A1 PROCESS FOR THE PREPARATION OF POLYMORPHS, SOLVATES OF ARIPIPRAZOLE USING ARIPIPRAZOLE ACID SALTS MATRIX LABORATORIES LTD (IN) 2006-03-23 WO claimed
WO-2006001846-A1 METHOD OF MAKING 7-(4-BROMOBUTOXY)-3,4-DIHYDROCARBOSTYRIL TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2006-01-05 WO claimed
US-20050215585-A1 Method of making 7-(4-bromobutoxy)-3,4-dihydrocarbostyril TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2005-09-29 US claimed
US-20050215791-A1 Process for preparing aripiprazole TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2005-09-29 US claimed
WO-2005077904-A1 PROCESS FOR PREPARING ARIPIPRAZOLE TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) 2005-08-25 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130744-A1 PROCESS FOR THE PREPARATION OF ARIPIPRAZOLE CYP3A4, CYP2C19, CYP2F1 MAOB 70/4885MAOA 78/4885
US-20060258869-A1 Process for the preparation of aripiprazole CYP2F1, CYP3A4, CYP2A7 MAOB 133/4885MAOA 260/4885
US-20090198059-A1 Process for the preparation of polymorphs, solvates of aripiprazole using aripirazole acid salts CYP3A4, CYP3A5, CYP3A43 MAOB 324/4885MAOA 142/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.